Company News

Myocardial Solutions Named Top 50 Most Innovative Companies to Watch in 2020

May 28, 2020
Company News

MORRISVILLE, N.C., May 28, 2020 – Myocardial Solutions, Inc. (MSI) was recognized in an article published by the CEO Views describing their selection for the “Most Innovative Companies to Watch in 2020” yearly list. The list highlights companies driving innovative technology solutions to challenge and transform the current standard of respective industry.

The CEO Views stated: “With an array of technology solutions for almost every problem, technology started growing and thus started growing the demands of humans. There upon came up several organizations with more innovative solutions. But only few companies could make it to the top level to be addressed as innovative companies.”

MSI aims to change the way cardiac and cancer patients are evaluated, monitored, and managed. MyoStrain® provides a novel approach, through its rapid, quantitative, and accurate proprietary technology, to shift the focus of cardiology towards prevention and management. With MyoStrain®, MSI helps empower physicians to overcome longstanding challenges faced in cardiology and may provide a new standard of care built on proactive diagnostics, personalized care, and improved clinical efficiency.

Full article by the CEO Views can be found here:


Media Contact

Ahmed Osman

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive MRI heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

To learn more about MyoStrain, visit or connect with us on LinkedIn and Twitter @myocardialsoln.